Mezzion Pharma Co.Ltd Asset Resilience Ratio
Mezzion Pharma Co.Ltd asset resilience ratio. Mezzion Pharma Co.Ltd (140410) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 140410 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Mezzion Pharma Co.Ltd (2015–2024)
Asset resilience ratio of Mezzion Pharma Co.Ltd from 2015 to 2024. This chart shows how Mezzion Pharma Co.Ltd's Asset Resilience Ratio has changed over time. See Mezzion Pharma Co.Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Mezzion Pharma Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Mezzion Pharma Co.Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩500.00 | 0.0% |
| Total Liquid Assets | ₩500.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Mezzion Pharma Co.Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mezzion Pharma Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Mezzion Pharma Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
|
Huons Global Co. Ltd
KQ:084110 |
Pharmaceuticals | 4.72% |
Mezzion Pharma Co.Ltd Asset Resilience Ratio by Year (2015–2024)
Mezzion Pharma Co.Ltd asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Mezzion Pharma Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.67% | ₩28.62 Billion ≈ $19.39 Million |
₩74.00 Billion ≈ $50.15 Million |
-24.54pp |
| 2023-12-31 | 63.21% | ₩58.25 Billion ≈ $39.47 Million |
₩92.15 Billion ≈ $62.45 Million |
+3.24pp |
| 2022-12-31 | 59.97% | ₩32.40 Billion ≈ $21.96 Million |
₩54.02 Billion ≈ $36.61 Million |
+3.73pp |
| 2021-12-31 | 56.24% | ₩47.21 Billion ≈ $31.99 Million |
₩83.93 Billion ≈ $56.88 Million |
-8.68pp |
| 2020-12-31 | 64.93% | ₩49.10 Billion ≈ $33.28 Million |
₩75.63 Billion ≈ $51.25 Million |
-4.98pp |
| 2019-12-31 | 69.91% | ₩41.16 Billion ≈ $27.89 Million |
₩58.87 Billion ≈ $39.90 Million |
-0.18pp |
| 2018-12-31 | 70.09% | ₩52.61 Billion ≈ $35.65 Million |
₩75.06 Billion ≈ $50.87 Million |
+0.23pp |
| 2017-12-31 | 69.86% | ₩51.72 Billion ≈ $35.05 Million |
₩74.04 Billion ≈ $50.17 Million |
+3.08pp |
| 2016-12-31 | 66.77% | ₩64.04 Billion ≈ $43.40 Million |
₩95.90 Billion ≈ $64.99 Million |
+44.36pp |
| 2015-12-31 | 22.42% | ₩23.10 Billion ≈ $15.66 Million |
₩103.05 Billion ≈ $69.84 Million |
-- |
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more